163 related articles for article (PubMed ID: 25888905)
21. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
Hofni A; El-Moselhy MA; Taye A; Khalifa MM
Eur J Pharmacol; 2014 Dec; 744():173-82. PubMed ID: 25446917
[TBL] [Abstract][Full Text] [Related]
22. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan.
Tsukuda K; Mogi M; Li JM; Iwanami J; Min LJ; Sakata A; Fujita T; Iwai M; Horiuchi M
Hypertension; 2007 Dec; 50(6):1099-105. PubMed ID: 17968000
[TBL] [Abstract][Full Text] [Related]
23. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
Sen S; Kanter M; Ustundag S; Aktas C; Dogutan H; Yalcin O
Ren Fail; 2008; 30(10):1023-33. PubMed ID: 19016156
[TBL] [Abstract][Full Text] [Related]
24. Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
Sebeková K; Lill M; Boor P; Heidland A; Amann K
Am J Nephrol; 2009; 29(3):164-70. PubMed ID: 18753741
[TBL] [Abstract][Full Text] [Related]
25. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
Anjaneyulu M; Chopra K
Am J Nephrol; 2004; 24(5):488-96. PubMed ID: 15353911
[TBL] [Abstract][Full Text] [Related]
26. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
27. Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist.
Kawata T; Daimon M; Hasegawa R; Teramoto K; Toyoda T; Sekine T; Yamamoto K; Uchida D; Himi T; Yoshida K; Komuro I
Am Heart J; 2006 Apr; 151(4):798.e9-15. PubMed ID: 16569537
[TBL] [Abstract][Full Text] [Related]
28. Neuroprotective effect of angiotensin II type 2 receptor stimulation in vincristine-induced mechanical allodynia.
Bessaguet F; Danigo A; Bouchenaki H; Duchesne M; Magy L; Richard L; Sturtz F; Desmoulière A; Demiot C
Pain; 2018 Dec; 159(12):2538-2546. PubMed ID: 30086116
[TBL] [Abstract][Full Text] [Related]
29. Involvement of angiotensin II type 1 receptor on pathological remodeling and dysfunction in obstructed bladder.
Aikawa K; Sakai T; Ishibashi K; Shiomi H; Sagawa K; Kumagai S; Kataoka M; Akaihata H; Yamaguchi O
Int J Urol; 2012 May; 19(5):457-64. PubMed ID: 22320898
[TBL] [Abstract][Full Text] [Related]
30. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
[TBL] [Abstract][Full Text] [Related]
31. Candesartan and insulin reduce renal sympathetic nerve activity in hypertensive type 1 diabetic rats.
Takimoto C; Kumagai H; Osaka M; Sakata K; Onami T; Kamayachi T; Iigaya K; Hayashi K; Saruta T; Itoh H
Hypertens Res; 2008 Oct; 31(10):1941-51. PubMed ID: 19015602
[TBL] [Abstract][Full Text] [Related]
32. Telmisartan improves vascular function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus.
Schäfer A; Flierl U; Vogt C; Menninger S; Tas P; Ertl G; Bauersachs J
Pharmacol Res; 2007 Sep; 56(3):217-23. PubMed ID: 17669665
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
Fu H; Hosomi N; Pelisch N; Nakano D; Liu G; Ueno M; Miki T; Masugata H; Sueda Y; Itano T; Matsumoto M; Nishiyama A; Kohno M
J Hypertens; 2011 Nov; 29(11):2210-9. PubMed ID: 21934531
[TBL] [Abstract][Full Text] [Related]
34. Effects of angiotensin type-1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus.
Malik RA; Schofield IJ; Izzard A; Austin C; Bermann G; Heagerty AM
Hypertension; 2005 Feb; 45(2):264-9. PubMed ID: 15630048
[TBL] [Abstract][Full Text] [Related]
35. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.
Rizzoni D; Porteri E; De Ciuceis C; Sleiman I; Rodella L; Rezzani R; Paiardi S; Bianchi R; Ruggeri G; Boari GE; Muiesan ML; Salvetti M; Zani F; Miclini M; Rosei EA
Hypertension; 2005 Apr; 45(4):659-65. PubMed ID: 15723969
[TBL] [Abstract][Full Text] [Related]
36. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
[TBL] [Abstract][Full Text] [Related]
37. The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance.
Yoshida O; Hirayama H; Nanasato M; Watanabe T; Murohara T
Am Heart J; 2005 Jan; 149(1):e2. PubMed ID: 15660025
[TBL] [Abstract][Full Text] [Related]
38. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Fogari R; Corradi L; Zoppi A; Lazzari P; Mugellini A; Preti P; Rinaldi A
Am J Hypertens; 2007 Oct; 20(10):1092-6. PubMed ID: 17903693
[TBL] [Abstract][Full Text] [Related]
39. Gastric ulcer healing and stress-lesion preventive properties of pioglitazone are attenuated in diabetic rats.
Konturek PC; Brzozowski T; Burnat G; Szlachcic A; Koziel J; Kwiecien S; Konturek SJ; Harsch IA
J Physiol Pharmacol; 2010 Aug; 61(4):429-36. PubMed ID: 20814070
[TBL] [Abstract][Full Text] [Related]
40. Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke.
Saad MA; Abbas AM; Boshra V; Elkhateeb M; El Aal IA
Acta Physiol Hung; 2010 Jun; 97(2):159-71. PubMed ID: 20511125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
